Published in Cancer Weekly, February 20th, 2007
STAT3 pathway inhibitors are a new class of drugs that were licensed to Callisto Pharmaceuticals from The University of Texas M. D. Anderson Cancer Center. The report, published in the journal Oncogene, describes studies with WP1066 on human malignant glioma (brain tumor) cells and in a mouse model of human brain cancer. Notably, WP1066 administered to mice significantly inhibited the growth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.